Related Experiment Video
Updated: Apr 6, 2026

Analyzing Large Protein Complexes by Structural Mass Spectrometry
Published on: June 19, 2010
Mass Spectrometric and Computational Investigation of the Protonated Carnosine-Carboplatin Complex Fragmentation
Ida Ritacco1, Emilia Sicilia1, Tamer Shoeib2,3
1†Dipartimento di Chimica e Tecnologie Chmiche, Università della Calabria, I-87036 Arcavacata di Rende, Italy.
Abstract:
Platinum(II)-based anticancer drugs are square-planar d(8) complexes that, activated by hydrolysis, cause cancer cell death by binding to nuclear DNA and distorting its structure. For that reason, interactions of platinum anticancer drugs with DNA have been extensively investigated, aiming at disentangling the mechanism of action and toxicity. Less attention, however, has been devoted to the formation of adducts between platinum drugs with biological ligands other than DNA. These adducts can cause the loss and deactivation of the drug before it arrives at the ultimate target and are also thought to contribute to the drug's toxicity. Here are reported the outcomes of electrospray ionization mass spectrometry experiments and density functional theory (DFT) computations carried out to investigate the fragmentation pathways of the protonated carnosine-carboplatin complex, [Carnosine + CarbPt + H](+). DFT calculations at the B3LYP/LANL2DZ level employed to probe fragmentation mechanisms account for all experimental data. Because of the relative rigidity of the structure of the most stable 1A conformer, stabilized by three strong hydrogen bonds, the first step of all of the examined fragmentation pathways is the interconversion of the 1A conformer into the less stable structure 1B. Formation of the [Carnosine + H](+) fragment from the precursor ion, [Carnosine + CarbPt + H](+), is calculated to be the lowest-energy process. At slightly higher energies, the loss of two amino groups is observed to produce the [Carnosine + (CarbPt - NH3) + H](+) and [Carnosine + (CarbPt - 2NH3) + H](+) ions. At significantly higher energies, the loss of CO2 occurs, yielding the final [Carnosine + (CarbPt - NH3) - CO2 + H](+) and [Carnosine + (CarbPt - 2NH3) - CO2 + H](+) products. Formation of the [CarbPt + H](+) fragment from [Carnosine + CarbPt + H](+), even if not hampered by a high activation barrier, is calculated to be very unfavorable from a thermodynamic point of view.
Insights
Researchers studied carnosine-carboplatin interactions using mass spectrometry and DFT. They found that carnosine can bind to carboplatin, influencing its fragmentation pathways and potentially affecting its anticancer efficacy and toxicity.
Area of Science:
- Chemical Biology
- Computational Chemistry
- Pharmacology
Background:
- Platinum(II)-based anticancer drugs like carboplatin are vital in cancer treatment.
- These drugs function by binding to DNA, but interactions with other biological molecules are less understood.
- Adducts with non-DNA ligands can reduce drug efficacy and increase toxicity.
Purpose of the Study:
- To investigate the fragmentation pathways of the carnosine-carboplatin complex.
- To understand the binding interactions between platinum anticancer drugs and biological ligands.
- To elucidate the potential impact of these interactions on drug mechanism and toxicity.
Main Methods:
- Electrospray ionization mass spectrometry (ESI-MS) was used to study the carnosine-carboplatin complex.
- Density functional theory (DFT) computations at the B3LYP/LANL2DZ level were employed to model fragmentation mechanisms.
- Experimental data was correlated with DFT calculations to validate fragmentation pathways.
Main Results:
- The study identified key fragmentation pathways for the protonated carnosine-carboplatin complex, [Carnosine + CarbPt + H](+).
- The lowest energy fragmentation pathway involves the formation of the [Carnosine + H](+) fragment.
- Higher energy pathways show the loss of ammonia and CO2 from the carboplatin moiety, yielding various adducts.
Conclusions:
- The carnosine-carboplatin complex undergoes distinct fragmentation pathways, influenced by its structure and energy.
- The formation of carnosine-drug adducts can lead to drug deactivation and altered toxicity profiles.
- Understanding these interactions is crucial for optimizing platinum-based cancer therapies.
More Related Videos
Related Concept Videos
Mass Spectrometry: Carboxylic Acid, Ester, and Amide Fragmentation
For example, the...
Mass Spectrometry: Molecular Fragmentation Overview
One type of fragmentation pattern is the cleavage of a single bond in the molecular ion. The cleavage leads to a radical and a cation. The cleavage can occur at...
Tandem Mass Spectrometry
Mass Spectrometry: Aromatic Compound Fragmentation
Mass Spectrometry: Cycloalkane Fragmentation
For example, cyclohexane molecular ions have a mass-to-charge ratio (m/z) of 84, which tends to produce a stronger signal than linear alkanes like hexane. This stability comes from...
NMR and Mass Spectroscopy of Carboxylic Acids
While α protons of carboxylic acids absorb at 2–2.5 ppm, β protons absorb further upfield.
Carboxylic acids are easily identified by dissolving them in deuterium oxide, which results in a rapid exchange of the acidic protons with deuterium. This leads to the...

